385 studies found for:    SKI
Show Display Options
Rank Status Study
1 Recruiting Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670
Condition: Uterine Disease
Interventions: Drug: SKI2670;   Drug: Placebo
2 Active, not recruiting Study to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome
Condition: Non-constipation Irritable Bowel Syndrome
Interventions: Drug: SKI3246 Low Dose;   Drug: SKI3246 High Dose;   Drug: Placebo
3 Active, not recruiting
Has Results
Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: SKI-606 (Bosutinib)
4 Completed
Has Results
Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty
Condition: Postoperative Pain
Interventions: Drug: SKY0402 + bupivacaine HCl;   Drug: Mid-dose SKY0402 + bupivacaine HCl
5 Completed Study Evaluating SKI-606 in Subject With Solid Tumors
Condition: Tumors
Intervention: Drug: SKI-606
6 Recruiting PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Conditions: Carcinoma;   Sarcoma;   Myeloma;   Lymphoma;   Melanoma
Interventions: Radiation: [18F]-SKI-249380;   Procedure: PET/CT scan;   Other: Blood draws
7 Completed
Has Results
Phase 2 Dose-Ranging Study of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy
Condition: Postoperative Pain
Interventions: Drug: SKY0402;   Drug: Bupivacaine HCl
8 Completed Study Evaluating 3 New Formulations of SKI-606 in Healthy Adult Subjects
Condition: Healthy
Intervention: Drug: SKI-606
9 Active, not recruiting
Has Results
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Bosutinib
10 Completed Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects
Conditions: Pain;   Hepatic Impairment
Interventions: Drug: SKY0402 300mg in healthy patients;   Drug: SKY0402 300mg in hepatically impaired patients
11 Completed
Has Results
Evaluation of the Safety, Efficacy, and Pharmacokinetics of SKY0402 in Subjects Undergoing Inguinal Hernia Repair
Condition: Inguinal Hernia
Interventions: Drug: SKY0402;   Drug: Bupivacaine HCl
12 Completed
Has Results
Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
Conditions: Breast Neoplasms;   Neoplasm Metastasis
Intervention: Drug: SKI-606 (Bosutinib)
13 Recruiting European Stop Tyrosine Kinase Inhibitor Study
Condition: Chronic Myeloid Leukemia
Intervention: Other: Stopping treatment with TKI
14 Completed
Has Results
Study of Pain Control in Hemorrhoidectomy
Condition: Hemorrhoid
Interventions: Drug: SKY0402;   Drug: Placebo
15 Completed
Has Results
Safety, Efficacy, and Pharmacokinetics of SKY0402 Administered as a Nerve Block in Subjects Undergoing Bunionectomy
Condition: Postoperative Pain
Interventions: Drug: SKY0402;   Drug: Bupivacaine HCl
16 Completed Study Evaluating SKI-606 Administered to Healthy Subjects
Condition: Healthy
Intervention: Drug: SKI-606
17 Completed
Has Results
Dose-ranging Study for Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair
Condition: Postoperative Pain
Interventions: Drug: Bupivacaine HCl;   Drug: SKY0402
18 Completed Study Evaluating Drug Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606
Condition: Healthy
Intervention: Drug: SKI-606
19 Completed Evaluate the Onset of Action of SKY0402 Following Local Infiltration in Healthy Volunteers
Condition: Postoperative Pain Management
Interventions: Drug: SKY0402;   Drug: Placebo
20 Completed
Has Results
A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty
Condition: Postoperative Pain
Interventions: Drug: Bupivacaine HCl;   Drug: SKY0402

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years